Vistin Pharma

"Management adopts a factual, operationally-focused tone that is neither notably bullish nor defensive. Positives (volume growth of 13%, strong balance sheet, dividend payment) are presented alongside clear negatives (EBITDA down 33% YoY, gross margin compression to 57%, Q4 production stop)."